Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Brain ventricular enlargement in human and murine acute intermittent porphyria.
Jericó D, Luis EO, Cussó L, Fernández-Seara MA, Morales X, Córdoba KM, Benito M, Sampedro A, Larriva M, Ramírez MJ, de Salamanca RE, Ortiz-de-Solorzano C, Alegre M, Prieto J, Lanciego JL, D'Avola D, González-Aseguinolaza G, Pastor MA, Desco M, Fontanellas A. Jericó D, et al. Among authors: de salamanca re. Hum Mol Genet. 2020 Nov 25;29(19):3211-3223. doi: 10.1093/hmg/ddaa204. Hum Mol Genet. 2020. PMID: 32916704
Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
Unzu C, Sampedro A, Mauleón I, Vanrell L, Dubrot J, de Salamanca RE, González-Aseguinolaza G, Melero I, Prieto J, Fontanellas A. Unzu C, et al. Among authors: de salamanca re. J Hepatol. 2010 Mar;52(3):417-24. doi: 10.1016/j.jhep.2009.09.003. Epub 2009 Sep 23. J Hepatol. 2010. PMID: 19815305 Free article.
Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice.
Unzu C, Sampedro A, Mauleón I, Alegre M, Beattie SG, de Salamanca RE, Snapper J, Twisk J, Petry H, González-Aseguinolaza G, Artieda J, Rodríguez-Pena MS, Prieto J, Fontanellas A. Unzu C, et al. Among authors: de salamanca re. Mol Ther. 2011 Feb;19(2):243-50. doi: 10.1038/mt.2010.210. Epub 2010 Sep 28. Mol Ther. 2011. PMID: 20877347 Free PMC article.
Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
D'Avola D, López-Franco E, Sangro B, Pañeda A, Grossios N, Gil-Farina I, Benito A, Twisk J, Paz M, Ruiz J, Schmidt M, Petry H, Harper P, de Salamanca RE, Fontanellas A, Prieto J, González-Aseguinolaza G. D'Avola D, et al. Among authors: de salamanca re. J Hepatol. 2016 Oct;65(4):776-783. doi: 10.1016/j.jhep.2016.05.012. Epub 2016 May 17. J Hepatol. 2016. PMID: 27212246 Free article. Clinical Trial.
Precipitating/aggravating factors of porphyria cutanea tarda in Spanish patients.
Cruz-Rojo J, Fontanellas A, Morán-Jiménez MJ, Navarro-Ordóñez S, García-Bravo M, Méndez M, Muñoz-Rivero MC, de Salamanca RE. Cruz-Rojo J, et al. Among authors: de salamanca re. Cell Mol Biol (Noisy-le-grand). 2002 Dec;48(8):845-52. Cell Mol Biol (Noisy-le-grand). 2002. PMID: 12699242
Human leukocyte antigen haplotypes and HFE mutations in Spanish hereditary hemochromatosis and sporadic porphyria cutanea tarda.
Gonzalez-Hevilla M, de Salamanca RE, Morales P, Martínez-Laso J, Fontanellas A, Castro MJ, Rojo R, Moscoso J, Zamora J, Serrano-Vela JI, Arnaiz-Villena A. Gonzalez-Hevilla M, et al. Among authors: de salamanca re. J Gastroenterol Hepatol. 2005 Mar;20(3):456-62. doi: 10.1111/j.1440-1746.2005.03553.x. J Gastroenterol Hepatol. 2005. PMID: 15740492
53 results